Carisma Therapeutics is developing novel chimeric antigen receptor (CAR) macrophage technology to treat solid tumors. Engineering T cells with CARs has shown great advances in the treatment of hematologic malignancies, but such results have not been translated to solid tumors. Macrophages are a key component of the immune system that eat cancer cells from solid tumors. Carisma is engineering macrophages with CARs to redirect their activity towards tumor cells to provide long-term anti-tumor immunity. Carisma’s lead candidate, CT-0508, is an ex vivo gene-modified autologous therapy to treat HER2 solid tumors in Phase 1 development. Carisma is also working on allogeneic CAR-Macrophages that would provide an off-the-shelf product enabling more patients to benefit from their cell therapies.

<p>Claim company profile to add description</p>


Carisma Therapeutics

Founded: 2017
Location: Philadelphia, PA
Employee range: 11 - 50
Clinical stage: Clin1
Therapy area: Solid tumors
Drug types: ONC
Lead product: CT-0508
Funding: $12M B Mar 2021; $47M B Jan 2021; $53M A Jul 2018

Drug notes:

About:

Jobs: